Company intelligence / Profile preview
Zetagen Therapeutics
Syracuse, New York, United Stateszetagen.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Zetagen’s lead candidate, ZetaMet™ (Zeta‑BC‑003), is in a Phase IIa clinical trial for metastatic breast cancer in the spine. The company has received multiple FDA Breakthrough Designations and has published results from compassionate use cases. Preclinical data support efficacy of other pipeline assets targeting metastatic cancers to bone and soft tissue organs.
- Therapeutic areas
- OncologyOther
- Modalities
- Small moleculesProprietary drug-carrier platformsHydrogel carriers
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Foley & Lardner LLP – intellectual property counselUniversity of British Columbia – clinical trial site for Phase IIa study
Beyond the preview
Go deeper on Zetagen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zetagen Therapeutics.